CLAIMS

What is claimed is:

1. A method for the treatment of a psoriatic-related skin disorder, the method comprising administering to a patient diagnosed with the disorder a therapeutically effective amount of a pharmaceutical composition comprising a nucleoside analog prodrug.

2. The method of claim 1, wherein the psoriatic-related skin disorder is selected from a group consisting of plaque psoriasis, psoriatic arthritis, guttate psoriasis, inverse psoriasis, seborrheic psoriasis, nail psoriasis, psoriatic exfoliative erthroderm, and pustular psoriasis.

3. The method of claim 1, wherein the pharmaceutical composition comprises an acyclovir prodrug.

4. The method of claim 3, wherein the pharmaceutical composition comprises valacyclovir or an analog thereof.

5. The method of claim 4, wherein the pharmaceutical composition is administered orally.

6. The method of claim 5, wherein the pharmaceutical composition is administered orally at a dosage between 1 gram and 3 grams per day.

7. A method for the treatment of a psoriatic-related skin disorder, the method comprising orally administering to a patient diagnosed with the disorder a therapeutically effective amount of a pharmaceutical composition comprising a nucleoside analog or a prodrug thereof.

8. The method of claim 7, wherein the pharmaceutical composition comprises acyclovir or an acyclovir prodrug.

9. The method of claim 8, wherein the pharmaceutical composition comprises valacyclovir or an analog thereof.

10. The method of claim 9, wherein the pharmaceutical composition is administered orally at a dosage between 1 gram and 3 grams per day.

11. The method of claim 7 wherein the psoriatic-related disorder is selected from the group consisting of plaque psoriasis, psoriatic arthritis, guttate

psoriasis, inverse psoriasis, seborrheic psoriasis, nail psoriasis, generalized erythrodermic psoriasis (psoriatic exfoliative erythroderm), and pustular psoriasis.

12. Use of a nucleoside analog or a prodrug thereof in an oral pharmaceutical composition for the treatment of a psoriatic-related disorder.

13. The use of claim 12 wherein the nucleotide analog is acyclovir.

14. The use of claim 13 wherein the prodrug is valacyclovir or an analog thereof.

15. Use of a nucleoside analog prodrug in a pharmaceutical composition for the treatment of a psoriatic-related disorder.

16. The use of claim 15 wherein the nucleotide analog prodrug is a prodrug of acyclovir.

17. The use of claim 16 wherein the prodrug is valacyclovir or an analog thereof.

18. An article of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein the pharmaceutical composition comprises an amount of nucleoside analog prodrug effective to treat a psoriatic-related skin disorder, and wherein said packaging material comprises a label or package insert indicating that said pharmaceutical composition can be used for treating a psoriatic-related skin disorder.

19. The article of manufacture of claim 18, wherein the pharmaceutical composition comprises an amount of valacyclovir or analog thereof effective to treat a psoriatic-related skin disorder.

20. The article of manufacture of claim 18, wherein the label or package insert indicates that said pharmaceutical composition can be used for treating a psoriatic-related skin disorder selected from the group consisting of plaque psoriasis, psoriatic arthritis, guttate psoriasis, inverse psoriasis, seborrheic psoriasis, nail psoriasis, generalized erythrodermic psoriasis (psoriatic exfoliative erythroderm), and pustular psoriasis.